Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature.

Abstract:

:Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessment if abnormal hemopoietic populations were identified and where standard morphology, cytochemistry or immunophenotyping techniques were equivocal and unable to establish the diagnosis. Analysis of the antigen receptor genes (IgH gene and TCR gamma locus) was performed in 230 patients by either Southern blotting or the polymerase chain reaction (PCR). Clonal rearrangements of either loci could be demonstrated in 91/230 patients: 56/161 patients analyzed by Southern blotting and 48/125 analyzed by polymerase chain reaction. A subgroup of patients (n = 88) was analyzed for rearrangement of the immunoglobulin heavy chain gene by both techniques. Discordant results were observed in 18 of these patients (20%). Analysis of the TCR gamma locus in a separate group demonstrated discordant results in eight of 40 patients examined (20%). Clinical outcome could be available in 61 patients (median time: 42 months, range 1-68 months): for those in whom a rearrangement was detected approximately 80% went on to develop a lymphoproliferative disorder although this diagnosis was not able to be made at the time the sample was taken. In a subset of patients (n = 14) who presented with lymphocytosis after bone marrow transplantation (seven) or solid organ transplant (seven), clonal lymphoid populations were demonstrated in approximately 50% of cases. The majority of these cases demonstrated the presence of Epstein-Barr virus (EBV) by PCR. The clonality of EBV infection was assessed by Southern blotting and the significance of these findings are discussed. This study explores the differences between Southern blotting and PCR as applied to the study of antigen receptor rearrangement studies. We conclude that detecting a clonal population is valuable in patients where standard diagnostic techniques are equivocal. However, the inability to detect a clonal population should be treated with caution and interpreted in light of other investigations.

journal_name

Leukemia

journal_title

Leukemia

authors

Rockman SP

doi

10.1038/sj.leu.2400678

subject

Has Abstract

pub_date

1997-06-01 00:00:00

pages

852-62

issue

6

eissn

0887-6924

issn

1476-5551

journal_volume

11

pub_type

杂志文章,评审

相关文献

LEUKEMIA文献大全
  • Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.

    abstract::Transcriptional regulation of the HOXA genes is thought to involve CTCF-mediated chromatin loops and the opposing actions of the COMPASS and Polycomb epigenetic complexes. We investigated the role of these mechanisms at the HOXA cluster in AML cells with the common NPM1c mutation, which express both HOXA and HOXB gene...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0856-3

    authors: Ghasemi R,Struthers H,Wilson ER,Spencer DH

    更新日期:2020-05-12 00:00:00

  • Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia.

    abstract::The number of long-term survivors of patients with acute myeloblastic leukemia (AML) has increased as a result of the progress of chemotherapy. We examined the recovery of peripheral blood lymphocytes (PBL) subset after chemotherapy to clarify the reconstitution of the immune system in AML. Thirty patients with AML in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400891

    authors: Ohnishi K,Yamanishi H,Naito K,Utsumi M,Yokomaku S,Hirabayashi N,Ohno R

    更新日期:1998-01-01 00:00:00

  • FHL2 regulates hematopoietic stem cell functions under stress conditions.

    abstract::FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under regenerative stress. We find that Fhl2 loss has limited effects on hemat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.254

    authors: Hou Y,Wang X,Li L,Fan R,Chen J,Zhu T,Li W,Jiang Y,Mittal N,Wu W,Peace D,Qian Z

    更新日期:2015-03-01 00:00:00

  • Complex landscape of alternative splicing in myeloid neoplasms.

    abstract::Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with littl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-1002-y

    authors: Hershberger CE,Moyer DC,Adema V,Kerr CM,Walter W,Hutter S,Meggendorfer M,Baer C,Kern W,Nadarajah N,Twardziok S,Sekeres MA,Haferlach C,Haferlach T,Maciejewski JP,Padgett RA

    更新日期:2020-08-04 00:00:00

  • A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

    abstract::We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen. Fifteen patients with advanced leukemia (12 with acute myeloid leukemia, 2 with acute lymphoblastic leukemia, 1 with biphenotypic) and...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.132

    authors: Pratz KW,Cho E,Levis MJ,Karp JE,Gore SD,McDevitt M,Stine A,Zhao M,Baker SD,Carducci MA,Wright JJ,Rudek MA,Smith BD

    更新日期:2010-08-01 00:00:00

  • Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

    abstract::Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, including the FLT3-ITD allelic ratio. PRT consisted of reduce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.183

    authors: Versluis J,In 't Hout FE,Devillier R,van Putten WL,Manz MG,Vekemans MC,Legdeur MC,Passweg JR,Maertens J,Kuball J,Biemond BJ,Valk PJ,van der Reijden BA,Meloni G,Schouten HC,Vellenga E,Pabst T,Willemze R,Löwenberg B,O

    更新日期:2017-01-01 00:00:00

  • Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

    abstract::Imatinib has pronounced antileukemic activity in Ph+ALL, although responses are usually short. To determine whether imatinib may facilitate allogeneic SCT in relapsed or refractory Ph+ALL, we evaluated 46 consecutive, not previously transplanted patients who were enrolled in phase II studies of imatinib. Of 30 patient...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2402770

    authors: Wassmann B,Pfeifer H,Scheuring U,Klein SA,Gökbuget N,Binckebanck A,Martin H,Gschaidmeier H,Hoelzer D,Ottmann OG

    更新日期:2002-12-01 00:00:00

  • Successful short-term ex vivo expansion of NOD/SCID repopulating ability and CAFC week 6 from umbilical cord blood.

    abstract::In view of the limited potential for rapid hematological recovery after transplantation of umbilical cord blood cells (UCB) in adults, we have attempted to expand CD34+ selected hemopoietic stem cells (HSC) and progenitors in 2-week cultures of whole graft pools in the presence or absence of serum and stromal layers, ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401917

    authors: Kusadasi N,van Soest PL,Mayen AE,Koevoet JL,Ploemacher RE

    更新日期:2000-11-01 00:00:00

  • Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.

    abstract::Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies,...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-01072-6

    authors: Wen T,Wang J,Shi Y,Qian H,Liu P

    更新日期:2020-10-29 00:00:00

  • Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.

    abstract::Currently available data regarding the substrate specificity of the multi-drug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-associated protein (MRP1) for idarubicin are inconclusive. A multiparameter flow cytometry method was developed which allows simultaneous quantitative measurement of total cellular fl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401496

    authors: Smeets ME,Raymakers RA,Vierwinden G,Pennings AH,Boezeman J,Minderman H,de Witte TM

    更新日期:1999-09-01 00:00:00

  • LIF mRNA expression is transcriptionally regulated in murine bone marrow stromal cells.

    abstract::Recent evidence has established an important role for leukemia inhibitory factor (LIF) as hematopoietically active cytokine. The present study utilized two different murine bone marrow stromal cell lines, +/+-1.LDA11 and MBA-13, to define regulatory mechanisms of LIF messenger RNA (mRNA) induction. LIF mRNA was not de...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Derigs HG,Boswell HS

    更新日期:1993-04-01 00:00:00

  • Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas.

    abstract::Gain of chromosome 18q and translocation t(14;18) are] frequently found in B-cell non-Hodgkin's lymphomas (B-NHL). Increased BCL2 transcription and BCL2 protein expression have been suggested to be the result of the gain. We utilized FISH, PCR and array CGH to study BCL2 and chromosome 18 copy number changes and rearr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403954

    authors: Galteland E,Sivertsen EA,Svendsrud DH,Smedshammer L,Kresse SH,Meza-Zepeda LA,Myklebost O,Suo Z,Mu D,Deangelis PM,Stokke T

    更新日期:2005-12-01 00:00:00

  • Identification of a favorable subgroup of patients with generalized immunocytomas by follicular dendritic cells.

    abstract::In the present study, 89 patients with generalized immunocytoma were analyzed retrospectively for the prognostic influence of clinical features and of immunophenotype using bone marrow biopsies. Univariate analysis selected the following variables as significant for survival: age over 60 years (p = 0.021), Rai and Bin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Eisterer W,Hilbe W,Fend F,Ludescher C,Falk M,Thaler J

    更新日期:1995-02-01 00:00:00

  • AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.

    abstract::Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patients of the previous study AML-BFM 93, and the non-DS groups of both studies. Compared to non-DS patients, DS pa...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2403814

    authors: Creutzig U,Reinhardt D,Diekamp S,Dworzak M,Stary J,Zimmermann M

    更新日期:2005-08-01 00:00:00

  • Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas.

    abstract::Several studies using sensitive in situ hybridization techniques show that, in non-immunocompromised patients, Epstein-Barr virus (EBV) is more frequently detected in lymphomas expressing T cell markers than in B cell lymphomas. Among lymphomas expressing T cell markers, the presence of EBV is highly related to the si...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Kanavaros P,Briere J,Emile JF,Gaulard P

    更新日期:1996-06-01 00:00:00

  • Identification of T-cell epitopes for cancer immunotherapy.

    abstract::The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins. Our...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404787

    authors: Kessler JH,Melief CJ

    更新日期:2007-09-01 00:00:00

  • Molecular investigation of the cytokines produced by normal and malignant B lymphocytes.

    abstract::Different normal and malignant human B-cell populations were studied with a twofold aim: to define which cytokines are produced in vivo, and to assess the relationship between cytokine production and kinetic state. To analyse normal B-cells representative of different stages of activation and proliferation in vivo, we...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Schena M,Gaidano G,Gottardi D,Malavasi F,Larsson LG,Nilsson K,Caligaris-Cappio F

    更新日期:1992-02-01 00:00:00

  • Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma.

    abstract::We analyzed nucleotide sequence and intraclonal diversity of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of CD5+ and CD5- diffuse large B cell lymphoma (DLBCL) to clarify the cell origin of de novo CD5+ DLBCL. Ten cases of CD5+ DLBCL and 29 cases of CD5- DLBCL were analyzed. The frequencie...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402031

    authors: Nakamura N,Kuze T,Hashimoto Y,Hara Y,Hoshi S,Sasaki Y,Shirakawa A,Sato M,Abe M

    更新日期:2001-03-01 00:00:00

  • Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

    abstract::A total of 1111 children with acute myeloblastic leukaemia (AML) were treated in four consecutive Berlin-Frankfurt-Münster (BFM) studies from 1978 to 1998. The first cooperative trial AML-BFM 78 established intensive chemotherapy with seven drugs, CNS irradiation and 2-year maintenance, achieving a long-term survival ...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2403920

    authors: Creutzig U,Zimmermann M,Ritter J,Reinhardt D,Hermann J,Henze G,Jürgens H,Kabisch H,Reiter A,Riehm H,Gadner H,Schellong G

    更新日期:2005-12-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract::Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.93

    authors: Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期:2014-10-01 00:00:00

  • Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

    abstract::In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.375

    authors: Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

    更新日期:2014-06-01 00:00:00

  • JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.

    abstract::The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.114

    authors: Zhan H,Ma Y,Lin CH,Kaushansky K

    更新日期:2016-12-01 00:00:00

  • Alpha interferon gene deletions in adults, children and infants with acute lymphoblastic leukemia.

    abstract::DNA from 76 cases of acute lymphoblastic leukemia (ALL) was tested with a cDNA probe encoding the alpha 2B interferon (IFN) gene transcript. Deletions were found in three of ten pre-B, three of 21 T-cell, four of 22 common and one of 23 null ALL cases. Amongst those with null ALL were 20 infants, most with characteris...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Middleton PG,Prince RA,Williamson IK,Taylor PR,Reid MM,Jackson GH,Katz F,Chessells JM,Proctor SJ

    更新日期:1991-08-01 00:00:00

  • Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.

    abstract::Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401559

    authors: Corradini P,Ladetto M,Pileri A,Tarella C

    更新日期:1999-11-01 00:00:00

  • Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.

    abstract::Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion of patients with myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor such mutations, which are often missense in type. Genotype-phenoty...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2012.86

    authors: Damm F,Nguyen-Khac F,Fontenay M,Bernard OA

    更新日期:2012-09-01 00:00:00

  • The effects of combinations of the recombinant growth factors GM-CSF, G-CSF, IL-3, and CSF-1 on leukemic blast cells in suspension culture.

    abstract::The blast cells of acute myeloblastic leukemia may be considered as a renewal population maintained by stem cells that are capable of both self-renewal and differentiation. Blast stem cells grow in culture usually when stimulated by growth factors normally active on myelopoietic cells. Two culture methods permit an ev...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miyauchi J,Kelleher CA,Wong GG,Yang YC,Clark SC,Minkin S,Minden MD,McCulloch EA

    更新日期:1988-06-01 00:00:00

  • Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.

    abstract::Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Griffiths SD,Cawley JC

    更新日期:1988-06-01 00:00:00

  • CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

    abstract::FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer pot...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0009-0

    authors: Jetani H,Garcia-Cadenas I,Nerreter T,Thomas S,Rydzek J,Meijide JB,Bonig H,Herr W,Sierra J,Einsele H,Hudecek M

    更新日期:2018-05-01 00:00:00

  • Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.

    abstract::Clinical characteristics, treatment response and outcome were evaluated in children with Down's syndrome (DS) and acute lymphoblastic leukemia (ALL) as compared to other children with ALL (NDS). Sixty-one DS and 4049 NDS patients, receiving intensive antileukemic treatment during four consecutive trials (ALL-BFM 81, 8...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400989

    authors: Dördelmann M,Schrappe M,Reiter A,Zimmermann M,Graf N,Schott G,Lampert F,Harbott J,Niemeyer C,Ritter J,Dörffel W,Nessler G,Kühl J,Riehm H

    更新日期:1998-05-01 00:00:00

  • A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

    abstract::This study was undertaken to determine the efficacy and toxicity of a shorter schedule of fludarabine administration (30 mg/m2 i.v. daily for 3 days every 4 weeks) in patients with previously treated chronic lymphocytic leukemia (CLL). Eighty patients with previously treated advanced (Rai III-IV) (54%) or progressive ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Robertson LE,O'Brien S,Kantarjian H,Koller C,Beran M,Andreeff M,Lerner S,Plunkett W,Keating MJ

    更新日期:1995-09-01 00:00:00